背景:饮食中的硫氨基酸限制(SAAR)可改善动物的代谢健康。在这项研究中,我们调查了饮食SAAR对体重的影响,身体成分,静息代谢率,白色脂肪组织(WAT)中的基因表达谱,以及超重或肥胖人群中广泛的血液生物标志物。
方法:N=59名超重或肥胖的参与者(73%的女性)按性别随机分层,进行为期8周的基于植物的低饮食干预(〜2g/天,SAAR)或高(~5.6克/天,对照组)在硫氨基酸中。向参与者提供了完整的饮食,研究者和参与者均对干预措施视而不见.使用线性混合模型回归对结果和性别的基线值进行校正,进行结果分析。
结果:与对照组相比,SAAR导致体重减轻约20%(β95%CI-1.14(-2.04,-0.25)kg,p=0.013)。尽管体重减轻更大,静息代谢率在组间保持相似.此外,SAAR降低血清瘦素,与对照组相比,酮体增加。在WAT,与对照相比,SAAR组中20个基因上调,而24个基因下调(FDR<5%)。通常适用的基因集富集分析显示,与核糖体相关的过程被上调,而与结构组分相关的过程下调。
结论:我们的研究表明,SAAR导致更大的体重减轻,与对照组相比,瘦素降低,酮体增加。需要对SAAR进行进一步研究,以研究人类代谢疾病的治疗潜力。
背景:ClinicalTrials.gov标识符:NCT04701346,注册于2021年1月8日,https://www。
结果:gov/study/NCT04701346。
Dietary sulfur amino acid restriction (SAAR) improves metabolic health in animals. In this study, we investigated the effect of dietary SAAR on body weight, body composition, resting metabolic rate, gene expression profiles in white adipose tissue (WAT), and an extensive blood biomarker profile in humans with overweight or obesity.
N = 59 participants with overweight or obesity (73% women) were randomized stratified by sex to an 8-week plant-based dietary intervention low (~ 2 g/day, SAAR) or high (~ 5.6 g/day, control group) in sulfur amino acids. The diets were provided in full to the participants, and both investigators and participants were blinded to the intervention. Outcome analyses were performed using linear mixed model regression adjusted for baseline values of the outcome and sex.
SAAR led to a ~ 20% greater weight loss compared to controls (β 95% CI - 1.14 (- 2.04, - 0.25) kg, p = 0.013). Despite greater weight loss, resting metabolic rate remained similar between groups. Furthermore, SAAR decreased serum leptin, and increased ketone bodies compared to controls. In WAT, 20 genes were upregulated whereas 24 genes were downregulated (FDR < 5%) in the SAAR group compared to controls. Generally applicable gene set enrichment analyses revealed that processes associated with ribosomes were upregulated, whereas processes related to structural components were downregulated.
Our study shows that SAAR leads to greater weight loss, decreased leptin and increased ketone bodies compared to controls. Further research on SAAR is needed to investigate the therapeutic potential for metabolic conditions in humans.
ClinicalTrials.gov identifier: NCT04701346, registered Jan 8th 2021, https://www.
gov/study/NCT04701346.